Skip to content
← Full study record

NCT04283773 · OUTCOME

P16 Evaluation in Ovarian Germ Cell Tumors

Immunohistochemical Evaluation of Protein P16 Expression in Ovarian Germ Cell Tumors. · Source last updated 2021-09-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
units on a scale
Interval / dispersion
Full Range
Time frame
Antibody exposure overnight, assessed up to 3 days for each run of sections assessed.

What was measured

For P16 IHC staining, the percentage of P16 positive cells and the location of positive signals (nuclear or cytoplasmic) were visually estimated for neoplastic components of all lesions. German Semi-quantitative scoring system were used to evaluate P16 expression as every tumor will be given a score according to the intensity of the cytoplasmic and nucleic staining (no staining = 0, weak staining = 1, moderate staining = 2, strong staining = 3) And the extent of stained cells (0% = 0, 1-10% = 1, 11-50% =2, 51-80% = 3, 81-100% = 4). The final immunoreactive score will be determined by multiplying the intensity scores with the extent of positivity scores of stained cells, with the minimum score of 0 and a maximum score of 12 ( score 0, 1,2,3,4,6,8,9 and 12).

Groups in this outcome

Malignant Ovarian Germ Cell Tumors ( MOGCTs).

22 cases of malignant ovarian germ cell tumors ; include Dysgerminoma , yolk sac tumor and immature teratomas will be treated by anti P16 antibody and Ki67 antibody. p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267): Treatment of slides that cut from paraffin embedded blocks related to groups by immunohistochemical method by p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267).Additional step for malignant cases , sections were treated by Ki67 antibody.

Mature Cystic Teratomas.

20 cases of mature teratomas will be treated by anti P16 antibody . p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267): Treatment of slides that cut from paraffin embedded blocks related to groups by immunohistochemical method by p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267).Additional step for malignant cases , sections were treated by Ki67 antibody.

Normally Apparent Ovaries.

20 cases of normally apparent ovaries will be treated by anti P16 antibody . p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267): Treatment of slides that cut from paraffin embedded blocks related to groups by immunohistochemical method by p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267).Additional step for malignant cases , sections were treated by Ki67 antibody.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Malignant Ovarian Germ Cell Tumors ( MOGCTs).22
Mature Cystic Teratomas.20
Normally Apparent Ovaries.20

Reported measurements

P16 cytoplasmic expression
Values in units on a scale · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Malignant Ovarian Germ Cell Tumors ( MOGCTs).7Not reported08Not reported
Mature Cystic Teratomas.4Not reported06Not reported
Normally Apparent Ovaries.0Not reported04Not reported
P16 nuclear expression
Values in units on a scale · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Malignant Ovarian Germ Cell Tumors ( MOGCTs).6Not reported08Not reported
Mature Cystic Teratomas.4Not reported05Not reported
Normally Apparent Ovaries.0Not reported03Not reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

  1. ci Lower Limit
    0
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    ci Upper Limit
    8
    dispersion Type
    STANDARD_DEVIATION
    dispersion Value
    1.5
    group Description
    Assessment of statistical differences in P16 expression between 3 groups. The immunohistochemical evaluation is done using German- semiquantitative scoring system. The score ranges from ( 0, 1,2,3,4,6,8,9 and 12). The data will entered on SPSS,version 24 as numbers. The test of significance is Kruskal Wallis was used to examine the Difference in Median between groups. Post-hoc test with Bonferroni Correction was used for Pairwise comparisons . A p-value \< 0.05 was considered significant.
    group Ids
    1. OG000
    2. OG001
    3. OG002
    non Inferiority Type
    SUPERIORITY
    p Value
    0.001
    p Value Comment
    The test of significance is Kruskal Wallis was used to examine the Difference in Median between groups. Post-hoc test with Bonferroni Correction was used for Pairwise comparisons . A p-value \< 0.05 was considered significant.
    param Type
    Median Difference (Final Values)
    param Value
    0.001
    statistical Method
    Kruskal-Wallis
Complete source fields
analyses
  1. ci Lower Limit
    0
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    ci Upper Limit
    8
    dispersion Type
    STANDARD_DEVIATION
    dispersion Value
    1.5
    group Description
    Assessment of statistical differences in P16 expression between 3 groups. The immunohistochemical evaluation is done using German- semiquantitative scoring system. The score ranges from ( 0, 1,2,3,4,6,8,9 and 12). The data will entered on SPSS,version 24 as numbers. The test of significance is Kruskal Wallis was used to examine the Difference in Median between groups. Post-hoc test with Bonferroni Correction was used for Pairwise comparisons . A p-value \< 0.05 was considered significant.
    group Ids
    1. OG000
    2. OG001
    3. OG002
    non Inferiority Type
    SUPERIORITY
    p Value
    0.001
    p Value Comment
    The test of significance is Kruskal Wallis was used to examine the Difference in Median between groups. Post-hoc test with Bonferroni Correction was used for Pairwise comparisons . A p-value \< 0.05 was considered significant.
    param Type
    Median Difference (Final Values)
    param Value
    0.001
    statistical Method
    Kruskal-Wallis
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0
        upper Limit
        8
        value
        7
      2. group Id
        OG001
        lower Limit
        0
        upper Limit
        6
        value
        4
      3. group Id
        OG002
        lower Limit
        0
        upper Limit
        4
        value
        0
    title
    P16 cytoplasmic expression
  2. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0
        upper Limit
        8
        value
        6
      2. group Id
        OG001
        lower Limit
        0
        upper Limit
        5
        value
        4
      3. group Id
        OG002
        lower Limit
        0
        upper Limit
        3
        value
        0
    title
    P16 nuclear expression
denoms
  1. counts
    1. group Id
      OG000
      value
      22
    2. group Id
      OG001
      value
      20
    3. group Id
      OG002
      value
      20
    units
    Participants
description
For P16 IHC staining, the percentage of P16 positive cells and the location of positive signals (nuclear or cytoplasmic) were visually estimated for neoplastic components of all lesions. German Semi-quantitative scoring system were used to evaluate P16 expression as every tumor will be given a score according to the intensity of the cytoplasmic and nucleic staining (no staining = 0, weak staining = 1, moderate staining = 2, strong staining = 3) And the extent of stained cells (0% = 0, 1-10% = 1, 11-50% =2, 51-80% = 3, 81-100% = 4). The final immunoreactive score will be determined by multiplying the intensity scores with the extent of positivity scores of stained cells, with the minimum score of 0 and a maximum score of 12 ( score 0, 1,2,3,4,6,8,9 and 12).
dispersion Type
Full Range
groups
  1. description
    22 cases of malignant ovarian germ cell tumors ; include Dysgerminoma , yolk sac tumor and immature teratomas will be treated by anti P16 antibody and Ki67 antibody. p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267): Treatment of slides that cut from paraffin embedded blocks related to groups by immunohistochemical method by p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267).Additional step for malignant cases , sections were treated by Ki67 antibody.
    id
    OG000
    title
    Malignant Ovarian Germ Cell Tumors ( MOGCTs).
  2. description
    20 cases of mature teratomas will be treated by anti P16 antibody . p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267): Treatment of slides that cut from paraffin embedded blocks related to groups by immunohistochemical method by p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267).Additional step for malignant cases , sections were treated by Ki67 antibody.
    id
    OG001
    title
    Mature Cystic Teratomas.
  3. description
    20 cases of normally apparent ovaries will be treated by anti P16 antibody . p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267): Treatment of slides that cut from paraffin embedded blocks related to groups by immunohistochemical method by p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267).Additional step for malignant cases , sections were treated by Ki67 antibody.
    id
    OG002
    title
    Normally Apparent Ovaries.
param Type
MEDIAN
reporting Status
POSTED
time Frame
Antibody exposure overnight, assessed up to 3 days for each run of sections assessed.
title
P16 Evaluation in Ovarian Germ Cell Tumors
type
PRIMARY
unit Of Measure
units on a scale

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice